The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

SOS1 Inhibitor (BAY 3498264)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

image_sqrt

Compound Overview

Kirsten rat sarcoma viral oncogene homolog (KRAS)/mitogen-activated protein kinase (MAPK) pathway dysregulation is among the most frequent drivers of cancer.1 Son of sevenless homolog 1 (SOS1) is a guanine nucleotide exchange factor that facilitates the activation of KRAS by promoting the exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP).2 Inhibiting SOS1 with SOS1 inhibitor (BAY 3498264) prevents KRAS activation, thereby disrupting downstream signaling through both the MAPK and phosphatidylinositol 3-kinase (PI3K) pathways.2-4

SOS1 inhibitor (BAY 3498264) is currently being evaluated in a phase I clinical trial involving patients with advanced KRAS G12C–mutated solid tumors.3

Tumor Types

Gastrointestinal cancer (colorectal, pancreatic)
Lung cancer
Solid tumors

Area of Research

MAPK signaling

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Lung Cancer, Solid Tumors, Gastrointestinal Cancer (Colorectal, Pancreatic)

I

Now Enrolling

Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors

NCT06659341

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.